anmelden
OMX Stockholm 30
3.282,94
PKT
+25,35
PKT
+0,78
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Stockholm 30-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 07.04.22 | Volvo (B) Neutral | JP Morgan Chase & Co. | |
| 06.04.22 | AstraZeneca Buy | Deutsche Bank AG | |
| 06.04.22 | ABB (Asea Brown Boveri) Outperform | Bernstein Research | |
| 05.04.22 | ABB (Asea Brown Boveri) Buy | UBS AG | |
| 05.04.22 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 05.04.22 | Hennes Mauritz (H M, H&M) Hold | Deutsche Bank AG | |
| 05.04.22 | Volvo (B) Buy | Jefferies & Company Inc. | |
| 04.04.22 | ABB (Asea Brown Boveri) Equal Weight | Barclays Capital | |
| 04.04.22 | ABB (Asea Brown Boveri) Hold | Jefferies & Company Inc. | |
| 01.04.22 | Hennes Mauritz (H M, H&M) Hold | Deutsche Bank AG | |
| 01.04.22 | Hennes Mauritz (H M, H&M) Sell | Goldman Sachs Group Inc. | |
| 31.03.22 | Hennes Mauritz (H M, H&M) Neutral | JP Morgan Chase & Co. | |
| 31.03.22 | Hennes Mauritz (H M, H&M) Outperform | RBC Capital Markets | |
| 31.03.22 | Hennes Mauritz (H M, H&M) Overweight | Barclays Capital | |
| 31.03.22 | Hennes Mauritz (H M, H&M) Hold | Jefferies & Company Inc. | |
| 31.03.22 | Hennes Mauritz (H M, H&M) Outperform | RBC Capital Markets | |
| 31.03.22 | Hennes Mauritz (H M, H&M) Sell | Goldman Sachs Group Inc. | |
| 31.03.22 | Hennes Mauritz (H M, H&M) Buy | UBS AG | |
| 31.03.22 | Hennes Mauritz (H M, H&M) Neutral | JP Morgan Chase & Co. | |
| 30.03.22 | AstraZeneca Buy | Deutsche Bank AG | |
| 29.03.22 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 25.03.22 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 25.03.22 | Volvo (B) Buy | Goldman Sachs Group Inc. | |
| 22.03.22 | AstraZeneca Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 21.03.22 | Hennes Mauritz (H M, H&M) Buy | UBS AG | |
| 21.03.22 | Hennes Mauritz (H M, H&M) Outperform | RBC Capital Markets | |
| 21.03.22 | Hennes Mauritz (H M, H&M) Neutral | JP Morgan Chase & Co. | |
| 18.03.22 | Hennes Mauritz (H M, H&M) Overweight | Barclays Capital | |
| 18.03.22 | AstraZeneca Buy | Deutsche Bank AG | |
| 16.03.22 | Hennes Mauritz (H M, H&M) Hold | Deutsche Bank AG | |
| 15.03.22 | Hennes Mauritz (H M, H&M) Overweight | JP Morgan Chase & Co. | |
| 15.03.22 | Hennes Mauritz (H M, H&M) Underperform | Credit Suisse Group | |
| 15.03.22 | AstraZeneca Buy | Deutsche Bank AG | |
| 15.03.22 | Hennes Mauritz (H M, H&M) Overweight | JP Morgan Chase & Co. | |
| 09.03.22 | ABB (Asea Brown Boveri) Outperform | Bernstein Research | |
| 09.03.22 | Hennes Mauritz (H M, H&M) Sell | Goldman Sachs Group Inc. | |
| 09.03.22 | Hennes Mauritz (H M, H&M) Underperform | Credit Suisse Group | |
| 08.03.22 | ABB (Asea Brown Boveri) Outperform | Bernstein Research | |
| 08.03.22 | AstraZeneca Buy | Deutsche Bank AG | |
| 07.03.22 | AstraZeneca Buy | UBS AG |
* Die angezeigten Realtime Kurse sind indikativ und nicht die offiziellen Börsenkurse. Die Kursdaten können eventuell vom tatsächlichen Marktpreis abweichen.
